Yes, Refill the Progesterone
The patient experienced an appropriate withdrawal bleed (5 days with 2 days of normal flow) after completing the 12-day cyclic progesterone regimen, which indicates the medication is working as intended—you should refill the prescription and continue the same monthly cyclic regimen. 1
Why This Response Confirms Treatment Success
Withdrawal bleeding occurring 2–5 days after stopping cyclic progesterone and lasting 4–7 days is the expected therapeutic response, demonstrating that the progestin successfully induced secretory transformation of the endometrium and then triggered organized shedding. 1
In the FDA pivotal trial of cyclic oral progesterone (10 mg medroxyprogesterone acetate for 12–14 days per month), 80% of women with secondary amenorrhea experienced withdrawal bleeding within 7 days of the last dose, confirming this is the desired outcome. 1
The patient's 5-day bleed with 2 days of "good" (normal-volume) menses falls squarely within the expected 4–7 day duration and indicates adequate endometrial protection against hyperplasia. 1
Continue the Current Regimen
Cyclic progesterone (10 mg nightly for 12 days each month) combined with evidence of ovulation (progesterone 7.3 ng/mL) provides endometrial protection by inducing monthly withdrawal bleeding, preventing the unopposed estrogen stimulation that leads to hyperplasia. 2
Sequential regimens using 10 mg medroxyprogesterone acetate or 200 mg micronized progesterone for 12–14 days per month are guideline-recommended doses for endometrial protection in women with anovulatory or irregular cycles. 2
The patient should continue taking one 10 mg pill nightly for 12 days each month (ideally the same calendar dates) and expect a period 2–5 days after stopping, as originally prescribed. 1
No Dose Adjustment or Referral Needed at This Time
Referral to gynecology for ultrasound or further evaluation is indicated only if the patient fails to have a withdrawal bleed within 10 days of stopping progesterone or if breakthrough bleeding occurs while taking the pills, neither of which has happened here. 3
Bleeding after stopping the progesterone is the intended therapeutic effect, not a complication or treatment failure. 1, 4
In the FDA-approved regimen, only 6% of women on cyclic progesterone plus estrogen developed hyperplasia over 36 months, compared to 64% on estrogen alone, demonstrating robust endometrial protection with this approach. 1
Patient Counseling for Ongoing Use
Reassure the patient that her bleeding pattern is normal and indicates the medication is protecting her uterine lining as intended. 3, 5
Emphasize consistent monthly timing (same 12 days each month) to maintain regular withdrawal bleeding and optimize endometrial protection. 3
Common side effects—bloating, breast tenderness, mood changes, headache, fatigue—typically improve after the first few cycles, so encourage continuation even if mild symptoms occur. 1
The patient should continue this regimen unless her cycles normalize spontaneously, she reaches menopause, or she decides to attempt conception. 2
When to Reassess
Contact the office if no withdrawal bleed occurs within 7–10 days after stopping a future cycle, as this may indicate inadequate endometrial buildup or need for dose adjustment. 1
Report any bleeding that starts during the 12 days of active progesterone use (not after stopping), as breakthrough bleeding on progesterone warrants evaluation for structural pathology. 3
Annual follow-up is appropriate to reassess ovulatory status, bleeding patterns, and continuation criteria. 2